Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents

Tsutomu Ishihara, Miyuki Takahashi, Megumu Higaki, Yutaka Mizushima, Tohru Mizushima

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

We have prepared polymeric nanoparticles using a blend of poly(lactic acid) and monomethoxy-polyethyleneglycol(PEG)-polylactide block copolymer along with betamethasone disodium phosphate (BP). Nanoparticles have been screened for anti-inflammatory activity using experimental rat models of inflammation. In the present study, we examined the degradation of nanoparticles in vitro during incubation. We found that the nanoparticles lost the PEG chains present on their surfaces within a few days, and subsequently gradually released BP. Furthermore, we found that these nanoparticles preferentially accumulated in the inflammatory lesion in adjuvant arthritis rat models, and that the amount of BP gradually depleted from the lesion over 14 days. These results suggested the mechanism underlying the anti-inflammatory effect of the nanoparticles in vivo: the initial accumulation of BP in the lesion due to the enhanced permeability and retention effect, the subsequent internalization in inflammatory macrophages due to the loss of PEG, and the release of BP in cells during the hydrolysis of polymers. The nanoparticles were successfully prepared on a large-scale and stably stored in the form of a freeze-dried formulation for at least 69 weeks below 25 °C. These results suggest that the nanoparticles can be used as an anti-inflammatory pharmaceutical formulation in a clinical setting.

Original languageEnglish
Pages (from-to)170-175
Number of pages6
JournalInternational Journal of Pharmaceutics
Volume385
Issue number1-2
DOIs
Publication statusPublished - 2010 Jan 29
Externally publishedYes

Fingerprint

Nanoparticles
Anti-Inflammatory Agents
Drug Compounding
Experimental Arthritis
Permeability
Polymers
Hydrolysis
Theoretical Models
Macrophages
betamethasone sodium phosphate
Inflammation

Keywords

  • Anti-inflammation
  • Block copolymer
  • Nanoparticle
  • PLA/PLGA
  • Storage stability

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents. / Ishihara, Tsutomu; Takahashi, Miyuki; Higaki, Megumu; Mizushima, Yutaka; Mizushima, Tohru.

In: International Journal of Pharmaceutics, Vol. 385, No. 1-2, 29.01.2010, p. 170-175.

Research output: Contribution to journalArticle

Ishihara, Tsutomu ; Takahashi, Miyuki ; Higaki, Megumu ; Mizushima, Yutaka ; Mizushima, Tohru. / Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents. In: International Journal of Pharmaceutics. 2010 ; Vol. 385, No. 1-2. pp. 170-175.
@article{fe2e014fad504ef9a7b2103ec81e01c3,
title = "Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents",
abstract = "We have prepared polymeric nanoparticles using a blend of poly(lactic acid) and monomethoxy-polyethyleneglycol(PEG)-polylactide block copolymer along with betamethasone disodium phosphate (BP). Nanoparticles have been screened for anti-inflammatory activity using experimental rat models of inflammation. In the present study, we examined the degradation of nanoparticles in vitro during incubation. We found that the nanoparticles lost the PEG chains present on their surfaces within a few days, and subsequently gradually released BP. Furthermore, we found that these nanoparticles preferentially accumulated in the inflammatory lesion in adjuvant arthritis rat models, and that the amount of BP gradually depleted from the lesion over 14 days. These results suggested the mechanism underlying the anti-inflammatory effect of the nanoparticles in vivo: the initial accumulation of BP in the lesion due to the enhanced permeability and retention effect, the subsequent internalization in inflammatory macrophages due to the loss of PEG, and the release of BP in cells during the hydrolysis of polymers. The nanoparticles were successfully prepared on a large-scale and stably stored in the form of a freeze-dried formulation for at least 69 weeks below 25 °C. These results suggest that the nanoparticles can be used as an anti-inflammatory pharmaceutical formulation in a clinical setting.",
keywords = "Anti-inflammation, Block copolymer, Nanoparticle, PLA/PLGA, Storage stability",
author = "Tsutomu Ishihara and Miyuki Takahashi and Megumu Higaki and Yutaka Mizushima and Tohru Mizushima",
year = "2010",
month = "1",
day = "29",
doi = "10.1016/j.ijpharm.2009.10.025",
language = "English",
volume = "385",
pages = "170--175",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents

AU - Ishihara, Tsutomu

AU - Takahashi, Miyuki

AU - Higaki, Megumu

AU - Mizushima, Yutaka

AU - Mizushima, Tohru

PY - 2010/1/29

Y1 - 2010/1/29

N2 - We have prepared polymeric nanoparticles using a blend of poly(lactic acid) and monomethoxy-polyethyleneglycol(PEG)-polylactide block copolymer along with betamethasone disodium phosphate (BP). Nanoparticles have been screened for anti-inflammatory activity using experimental rat models of inflammation. In the present study, we examined the degradation of nanoparticles in vitro during incubation. We found that the nanoparticles lost the PEG chains present on their surfaces within a few days, and subsequently gradually released BP. Furthermore, we found that these nanoparticles preferentially accumulated in the inflammatory lesion in adjuvant arthritis rat models, and that the amount of BP gradually depleted from the lesion over 14 days. These results suggested the mechanism underlying the anti-inflammatory effect of the nanoparticles in vivo: the initial accumulation of BP in the lesion due to the enhanced permeability and retention effect, the subsequent internalization in inflammatory macrophages due to the loss of PEG, and the release of BP in cells during the hydrolysis of polymers. The nanoparticles were successfully prepared on a large-scale and stably stored in the form of a freeze-dried formulation for at least 69 weeks below 25 °C. These results suggest that the nanoparticles can be used as an anti-inflammatory pharmaceutical formulation in a clinical setting.

AB - We have prepared polymeric nanoparticles using a blend of poly(lactic acid) and monomethoxy-polyethyleneglycol(PEG)-polylactide block copolymer along with betamethasone disodium phosphate (BP). Nanoparticles have been screened for anti-inflammatory activity using experimental rat models of inflammation. In the present study, we examined the degradation of nanoparticles in vitro during incubation. We found that the nanoparticles lost the PEG chains present on their surfaces within a few days, and subsequently gradually released BP. Furthermore, we found that these nanoparticles preferentially accumulated in the inflammatory lesion in adjuvant arthritis rat models, and that the amount of BP gradually depleted from the lesion over 14 days. These results suggested the mechanism underlying the anti-inflammatory effect of the nanoparticles in vivo: the initial accumulation of BP in the lesion due to the enhanced permeability and retention effect, the subsequent internalization in inflammatory macrophages due to the loss of PEG, and the release of BP in cells during the hydrolysis of polymers. The nanoparticles were successfully prepared on a large-scale and stably stored in the form of a freeze-dried formulation for at least 69 weeks below 25 °C. These results suggest that the nanoparticles can be used as an anti-inflammatory pharmaceutical formulation in a clinical setting.

KW - Anti-inflammation

KW - Block copolymer

KW - Nanoparticle

KW - PLA/PLGA

KW - Storage stability

UR - http://www.scopus.com/inward/record.url?scp=72149119067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149119067&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2009.10.025

DO - 10.1016/j.ijpharm.2009.10.025

M3 - Article

C2 - 19837147

AN - SCOPUS:72149119067

VL - 385

SP - 170

EP - 175

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -